| الم مشرية | OIPA | L SCA | · | | (| | P | OMB No | 0651-001 | 1 (12/31/86 | |
|---|--|-----------------------------------|---|-------------------------------------|--------------|------------------------|-----------------|---|------------------------------|---------------|--|
| AMENDMENT TRANSMITTAL LETTER SERIAL NO. FILING DATE EXAMINER | | | | | | | | MB No. 0651-0011 (12/31/86 ATTORNEY'S DOCKET NO. GJE-18D1 | | | |
| SERIAL NO. 10/015,162 FILING DATE December | | | | EXAMINER Shengjun Wang, Ph.D. | | | GROUP ART UNIT | | | | |
| INVENTION Compositi | | a Tissue Gl | ue and Therape | utic Agents | | | | Tx 4 | SO CE | W. | |
| INVENTION Compositions Comprising a Tissue Glue and Therapeutic Agents TO THE COMMISSIONER OF PATENTS AND TRADEMARKS: Transmitted herewith is an amendment in the above-identified application. Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted. | | | | | | | | | | | |
| Transmitted herewith is an amendment in the above-identified application. | | | | | | | | | | | |
| Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted. | | | | | | | | | | | |
| | A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed. | | | | | | | | | | |
| | | | | | | | | | | | |
| ☐ The fee has been calculated as shown below: | | | | | | | | | | | |
| (1) | | | (2) | (3) | SMALL ENTITY | | | | OTHER THAN A SMALL ENTITY | | |
| | CLAIMS REMAINING AFTER AMENDMENT | | HIGHEST NO. PREVIOUSLY PAID FOR | PRESENT EXTRA | | RATE | ADDIT. FEE | <u>OR</u> | RATE | ADDIT. FEE | |
| TOTAL | • 22 | MINUS | •• 20 | 2 | | \$ 9 | \$ 18.00 | | \$18 | \$0.00 | |
| INDEP. | • 9 | MINUS | ••• 7 | 2 | | \$42 | \$ 84.00 | | \$84 | \$0.00 | |
| FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM 1 | | | | | | \$140 | \$ 0.00 | | \$280 | \$0.00 | |
| | | | | • | | Total addit. fee | \$102.00 | OR | Total addit. fee | \$0.00 | |
| | | | · | | | | | | <u> </u> | | |
| ** If the Highe | est No. Previously P est No. Previously F | Paid For IN THI Paid For IN TH | Col. 2, write "0" in Co S SPACE is less th IS SPACE is less th r Indep.) is the high | an 20, enter "2 an 3, enter "3." | • | the appropri | ate box in Col. | 1. | | | |
| Please charge my Deposit Account No. 19-0065 in the amount of \$\frac{102.00}{}. | | | | | | | | | | | |
| | A check in the amount of \$ to cover the filing fee is enclosed. | | | | | | | | | | |
| ⊠ | · | | | | | | | | | | |
| Any additional filing fees required under 37 CFR 1.16. | | | | | | | | | | | |
| | ⊠ | Any p | atent application | processing for | ees u | nder 37 CI | FR 1.17. | | | | |
| Ma | rch 24, 2003 | | | | | | | | | | |
| (date) | | | | | (sign | ature) | | | | | |

Form PTO-FB-A520 (8-83) (also form PTO-1083)

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231 on

Examining Group 1617 Patent Application Docket No. GJE-18D1 Serial No. 10/015,162

AMENDMENT UNDE

Doran R. Pace, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Shengjun Wang, Ph.D.

Art Unit

1617

Applicants

Aaron Gershon Filler, Andrew Michael Lindsay Lever

Serial No.

10/015,162

Filed

December 11, 2001

Conf. No.

6118

For

Compositions Comprising a Tissue Glue and Therapeutic Agents

Assistant Commissioner for Patents

Washington, D.C. 20231

AMENDMENT UNDER 37 CFR §1.111

Sir:

A Petition and Fee for a two-month Extension of Time through and including March 24, 2003, accompanies this Amendment.

In response to the Office Action dated October 22, 2002, please amend the above-identified patent application as follows:

04/03/2003 EFLORES 00000008 190065 10015162

01 FC:2201 02 FC:2202

84.00 CH 18.00 CH

In the Claims

Please substitute the following claims:

Claim 1 (twice amended):

1. A composition comprising a tissue glue and, immobilized in the glue, in particulate form, a radiotherapeutic agent or an agent convertible to a radiotherapeutic, wherein the agent is immobilized in the glue for a period of time sufficient for a radiotherapeutic effect.